Man’s deadly brain cancer tumor disappears after experimental drug trial
A man with the deadliest form of brain cancer has no signs of the disease after taking an experimental drug.
Ben Trotman was 40 when he was diagnosed in 2022 with glioblastoma, the most aggressive cancerous brain tumor. Patients typically live an average of 15 months after diagnosis, and the five-year survival rate is just 6.9%.
Trotman was referred to The National Hospital for Neurology and Neurosurgery at University College London Hospitals (UCLH), where he was treated by consultant UCLH medical oncologist Dr. Paul Mulholland, as detailed in a press release.
ANCIENT 'PHARAOH'S CURSE' FUNGUS SHOWS PROMISE IN KILLING CANCER CELLS
As the only person enrolled in a trial that ultimately closed due to lack of patients, Trotman received a medication called ipilimumab, a targeted immunotherapy treatment.
Ipilimumab is an antibody that binds to a protein on immune cells (T cells). It keeps cancer cells from suppressing the immune system so it can then attack and kill the cancer..